MYCN-157 signature was identified through silencing MYCN in NB cells, and its high expression was found to be correlated with poor outcomes, regardless of MYCN amplified or non-amplified (Valentijn et al., 2012; Wei et al., 2018), which was in line with our study. This evidence concerns the gene MYCN and neuroblastoma.